Coronary heart disease (CHD) is a major cause of morbidity and mortality. Recent evidence supports the benefits of intensive low density lipoprotein-cholesterol (LDL-c) reduc-of intensive low density lipoprotein-cholesterol (LDL-c) reduction on CHD risk with various ongoing end point trials addressing the issue of optimal cholesterol reduction. Statins reduce LDL-c, and have been shown to reduce CHD event rates in both primary and secondary prevention trials. The magnitude of this effect is not fully accounted for by LDL-c reduction alone and may relate to effects on other lipid parameters.
Fibrates represent the best treatment for raising high density lipoprotein-cholesterol (HDL-c) and a variety of agents, which specifically target HDL-c, are under development.
New therapies being developed to meet the challenge of intensive cholesterol lowering include rosuvastatin, a potent statin, producing reductions in LDL-c of up to 69% and ezetimibe, a selective cholesterol absorption inhibitor, producing reductions in LDL-c of up to 25%.
This review summarises the evidence regarding dyslipidaemia and vascular risk and how advances in lipid-lowering therapy may be important in future management of hyperlipidaemia.
Kannel WB, Larson M.Long-term epidemiologic prediction of coronary disease. The Framingham experience . Cardiology1993;82:137-52.
2.
Stamler J., Daviglus ML, Garside DB, Dyer AR, Greenland P., Neato JDRelationship between baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular and all cause mortality and longevity. JAMA2000;284:311-18.
3.
Ross R.The pathogenesis of atherogenesis: A perspective for the 1990s. Nature1993;362:801-09.
4.
Scandinavian Simvastatin Survival group.Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344:1383-9.
5.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: A randomised placebo controlled trial. Heart Protection Study Collaborative group. Lancet2002;360:7-22.
6.
Stamler J., Vaccaro O., Neaton JD, Wentworth D. for the Multiple Risk factor Intervention Trial Research group.Diabetes, other risk factors and 12year cardiovascular mortality for men screened in the multiple risk factor intervention trial . Diabetes Care1993;16:343-4.
7.
The long-term intervention with pravastatin in ischaemic disease (LIPID) study group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl J Med1998;338:1349-57.
8.
Genest JJ, McNamara JR, Ordovas JM et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary heart disease. J Am Coll Cardiol1992;19:792-802.
9.
Assman G., Cullen P., Schulte H.The Munster Heart study (PROCAM): Results of follow up at 8 years. Eur Heart J1998;19(suppl A):A2-A11.
10.
Wilson PW, Anderson KM, Castelli WPTwelve year incidence of CHD in middle aged adults during the era of hypertensive therapy. The Framingham offspring study. Am J Med1991;90:276-82.
11.
Expert panel on Detection Evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA2001;285:2486-97.
12.
Wood D., De Backer G., Faegerman O. et al. Prevention of coronary heart disease in clinical practice: Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J1998;19:1434-503.
13.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA2002 ;288:2998-3007.
14.
Gotto AM Jr, Whitney E., Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation2000;101:477-84.
15.
Sacks FM, Tonkin AM, Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project . Circulation2000;102:1893-900.
16.
Assmann G.Pro and Con: High-density lipoprotein, triglycerides and other lipid subfractions are the future of lipid management. Am J Cardiol2001;87(suppl)2B-7B.
17.
Vosper H., Khoudoli GA, Graham TL, Palmer CNPeroxisome proliferatoractivated receptor agonists, hyperlipidaemia, and atherosclerosis . Pharmacol Ther2002;95(1):47-62.
18.
Robins SJ, Collins D., Wittes JT et al. VA-HIT Study Group.Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA2001;285:1585-91.
19.
The BIP study group.Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation2000;102:21-7.
20.
The DAIS study group.Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study . Lancet2001;357:905-10.
21.
Lu W., Resnick HE, Jablonski KA et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study. Diabetes Care2003;26(1):16-23.
22.
Frost PH, Davis BR, Burlando AJ et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation1996;94:2381-8.
23.
Cui Y., Blumenthal RS, Flaws JA et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med2001;161:1413-19.reductase inhibitors on skeletal
24.
Evans M., Rees A.Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?Drug Safety2002;25:649-63.
25.
Shek A., Ferrill MJStatin-fibrate combination therapy. Ann Pharmacother2001;35:908-17.
26.
Thompson GRExecutive summary of simvastatin. Journal of Drug Evaluation: Cardiovascular Medicine2002;1:53-88.
27.
Miettinen TA , Gylling H., Strandberg T., Sarna S.Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Finnish 4S Investigators. BMJ1998;316:1127-30.
28.
Dujovne CA, Ettinger MP, McNeer JF et al. Ezetimibe Study Group.Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol2002;90:1092-7.
29.
Davidson M. , Ma P., Stein E. et al. Comparison of effects on low density lipoprotein cholesterol and high density lipoprotein cholesterol with rosuvastatin vs. atorvastatin in patients with type IIa or IIb hypercholesterolaemia. Am J Cardiol2002;89:268-75.
30.
Hallikainen MA, Sarkkinen ES, Unsitupa MIPlant stanol esters affect serum cholesterol levels of hypercholesterolaemic men and women in a dose dependent manner. J Nutr2000;130:767-76.
31.
Catapano ALEzetimibe: A selective inhibitor of cholesterol absorption. Eur Heart J2001;3(suppl E)E6-E10.
32.
Patrick JE, Kosoglou T., Stauber KL et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos2002;30:430-7.
33.
Bays HE, Moore PB, Drehobl MA et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther2001;23:1209-30.
34.
Mori TA, Beilin LJLong-chain omega-3-fatty acids, blood lipids and cardiovascular risk reduction . Curr Opin Lipidol2001;12:11-17.
35.
Friedberg CE , Heine RJ, Janssen Mjfm, Grobbee DEFish oil and glycemic control in diabetes - a meta-analysis. Diabetes Care1998;21:494-500.
